Nectin Therapeutics is developing next-generation immuno-oncology antibodies and antibody-drug conjugates (ADCs) to target tumor escape mechanisms that contribute to resistance against existing therapies. Their pipeline includes a first-in-class anti-PVR asset currently in phase 1 clinical trials, aimed at improving response rates for the majority of cancer patients who do not benefit from approved immuno-oncology treatments.
Funding
$58M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GFounders
Product
Problem
Despite the efficacy of existing immuno-oncology (IO) therapies, a significant proportion of cancer patients either do not respond initially or develop resistance over time due to tumor escape mechanisms. This limits the overall success of IO treatments across various cancer types.
Solution
Nectin Therapeutics is developing next-generation immuno-oncology antibodies and antibody-drug conjugates (ADCs) designed to overcome tumor escape and resistance mechanisms. Their pipeline includes first-in-class and best-in-class programs, such as an anti-PVR asset currently in Phase 1 clinical trials. These therapies aim to improve patient response rates in advanced solid tumors by targeting key factors that limit the effectiveness of current IO treatments. Nectin's approach focuses on modulating the tumor microenvironment to enhance immune cell activity and promote durable anti-cancer responses.
Target Audience
The primary target audience includes cancer patients with advanced solid tumors who have not responded to or have developed resistance to existing immuno-oncology therapies, as well as oncologists and clinical researchers seeking novel treatment options.
Features
- Novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs) targeting tumor escape mechanisms
- First-in-class anti-PVR asset (NTX1088) in Phase 1 clinical trials for advanced solid tumors
- Focus on overcoming resistance to existing immuno-oncology therapies
- Pipeline of targeted immunotherapies designed to improve patient response rates